- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Crenolanib, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 177
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Interventions
- Mitoxantrone
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lymphoma
- Interventions
- Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
- Interventions
- Dexamethasone, Laboratory Biomarker Analysis, Methotrexate, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Temsirolimus, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 26 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- ITMHA, Dexamethasone, Mitoxantrone, Pegaspargase, Asparaginase Erwinia Chrysanthemi, Bortezomib, Vorinostat, Cyclophosphamide, Mercaptopurine, Methotrexate, Leucovorin Calcium, Cytarabine, Etoposide, Vincristine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 365 Days
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2031
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 6 more
- Conditions
- Leukemia
- Interventions
- asparaginase, busulfan, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, methotrexate, mitoxantrone hydrochloride, allogeneic bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 111 more
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
- Interventions
- Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia
- Interventions
- cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- filgrastim, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- Hope Cancer Institute, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas
- Conditions
- Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cladribine, Cytarabine, Decitabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma, Follicular
- Interventions
- inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 17
- States / cities
- Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more
- Conditions
- Leukemia
- Interventions
- lintuzumab, cytarabine, etoposide, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- Facet Biotech
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 40
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 29 more
- Conditions
- Myeloid Malignancies
- Interventions
- Magrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 13 more
- Conditions
- Leukemia
- Interventions
- sargramostim, mitomycin C, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
- Interventions
- Pixantrone (BBR 2778), fludarabine, dexamethasone, rituximab
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Baltimore, Maryland • Albuquerque, New Mexico + 1 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- sargramostim, cytarabine, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
- Interventions
- PD 0332991
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Prostate Cancer
- Interventions
- endocrine-modulating drug therapy, mitoxantrone hydrochloride, prednisone, prinomastat
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- bevacizumab, cytarabine, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Baltimore, Maryland
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride, cytarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Relapsed Adult AML, Refractory AML
- Interventions
- Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Lenalidomide, Mitoxantrone, Etoposide, Cytarabine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts